— Know what they know.
Not Investment Advice

PROGEN.ST STO

Prostatype Genomics AB (publ)
1W: -22.6% 1M: -35.6% 3M: -57.3% YTD: -92.4% 1Y: -86.5% 3Y: -100.0% 5Y: -100.0%
kr 0.09 ($0.01)
-0.00 (-1.27%)
 
Weekly Expected Move ±15.2%
kr 0 kr 0 kr 0 kr 0 kr 0
STO · Healthcare · Medical - Diagnostics & Research · Tech Score Strong Sell · Power 33 · kr 3.1M mcap · 31M float · 16.96% daily turnover

Balance Sheet Trends

Total Assets
$51M +21.2% ▲
5Y CAGR: +8.6%
Total Liabilities
$24M +186.2% ▲
5Y CAGR: +35.3%
Shareholders Equity
$27M -20.7% ▼
5Y CAGR: -1.3%
Cash & Investments
$9M -3.7% ▼
5Y CAGR: -10.6%
Total Debt
$0 -100.0% ▼
Net Debt
-$9M +3.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$10M$5M$3M$9M$9M
Short-Term Investments$10M$7M$0$0$0
Cash & ST Investments$20M$11M$3M$9M$9M
Net Receivables$1M$2M$2M$2M$1M
Inventory$108K$44K$203K$95K$78K
Other Current Assets$0$1K$21M-$149K$0
Total Current Assets$22M$14M$26M$12M$11M
Property, Plant & Equip.$14K$4K$60K$312K$452K
Goodwill & Intangibles$19M$17M$23M$29M$39M
Long-Term Investments$0$68K$72K$566K$485K
Other Non-Current Assets$0-$1K$0$0-$1K
Total Non-Current Assets$19M$17M$23M$30M$40M
Total Assets$40M$31M$49M$42M$51M
— Liabilities —
Accounts Payable$1M$2M$9M$3M$0
Short-Term Debt$400K$400K$12M$67K$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$2M$3M$6M$24M
Total Current Liabilities$3M$4M$24M$9M$24M
Long-Term Debt$867K$467K$67K$0$0
Other Non-Current Liab.$0-$333-$1K$0-$1K
Total Non-Current Liabilities$867K$467K$66K$0-$1K
Total Liabilities$4M$5M$25M$9M$24M
— Equity —
Common Stock$905K$1M$7M$670K$6M
Retained Earnings-$114M-$141M$0$0$0
Accumulated OCI$19M$17M-$160M-$151M$0
Total Stockholders Equity$36M$26M$25M$33M$27M
Total Liabilities & Equity$40M$31M$49M$42M$51M
— Key Metrics —
Total Debt$1M$867K$12M$67K$0
Net Debt-$9M-$4M$9M-$9M-$9M
Total Investments$10M$7M$72K$566K$485K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms